News
November 7th 2008
Orphan Drug status in the USA
SymbioTec was granted the Orphan Medicinal Product Designation in the USA for the active ingredients of ONCOHIST for the treatment of Acute Myeloid Leukemia by the Food and Drug Administration on 20th October 2008.
News Archive
November 2009: Phase IIB Clinical Trial ARAHIST-09 In November 2009 the open ...November 17th 2009: SymbioTec Wins Contest SymbioTec was elected ...
March 4th 2009: License Agreement with Cryonics In 2008 SymbioTec has signed ...
November 7th 2008: Orphan Drug status in the USA SymbioTec was granted ...
January 11th 2008: Orphan Drug status for SymbioTec On December 20th 2007 the ...
Downloads
365 Landmarks in the Land of Ideas (PDF) (556 KB)Press Release March 2009 (PDF) (112.1 KB)
Abstract ASH Meeting Dec 2007 (PDF) (12.3 KB)
Poster Freiburg Sep 2007 (PDF) (9.3 KB)
Press Release Feb 2005 (PDF) (9.5 KB)